Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Phase II Study in Patients With Resected, Stage II High Risk and Stage III Colorectal Cancer
A Phase II Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
A Phase III Open-Label, Multicenter, Randomized, Active-Controlled Study to Compare the Efficacy, Pharmacokinetics, Safety, and Tolerability of P1101 vs Anagrelide as Second-Line Therapy for Essential Thrombocythemia.
A Phase II study of TAS-102 in metastatic Platinum and checkpoint inhibitor?resistant bladder cancer
A Phase III RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy PROSPER RCC
Study Type: Treatment
Phase: III
NCTID: NCT03055013
Principal Investigator:
Elizabeth Wulff-Burchfield
A Randomized Phase III Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Efficacy of Point Of Service Testing in Metastatic Breast Cancer E-POST MBC
A Phase III, Open-Label, Randomized, Parallel Group Study to Evaluate the Efficacy and Safety of Intrapleural Administration of Adenovirus-Delivered Interferon Alpha-2b rAd-IFN in Combination with Celecoxib and Gemcitabine in Patients with Malignant Pleural Mesothelioma
A Phase III Randomized Open-label Multicenter Study of the Efficacy and Safety of Pyrotinib versus Docetaxel in Patients with Advanced Non-squamous Non-small Cell Lung Cancer NSCLC Harboring a HER2 Exon 20 Mutation who Progressed on or after Treatment with Platinum Based Chemotherapy
Study Type: Treatment
Phase: III
NCTID: NCT04447118
Principal Investigator:
Jun Zhang
A Multi-Center Phase II Study of Ipatasertib in Combination with Docetaxel in Metastatic/Advanced NSCLC Patients Who Have Failed or Are Intolerant to 1st Line Immunotherapy
Study Type: Treatment
Phase: II
NCTID: NCT04467801
Principal Investigator:
Jun Zhang